NMN for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

NMN for Health & Longevity

Created on 09/22/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

NMN is a dietary supplement related to vitamin B3, sold to raise a coenzyme — a helper molecule the body needs for energy release and DNA repair. It does that dependably in blood. Beyond that, evidence thins: a small drop in the lower blood-pressure number past age sixty, single-trial hints on sleep, endurance and muscle sugar handling. Safety over months looks reassuring; nothing has run beyond six months. (Full Review)

Protocol

Standard dose range
250–600 mg/day
Orally. Blood NAD+ and walking distance peaked around 600 mg/day, with no further gain at 900 mg.
Best time of day
Morning
The convention, justified by the daily rhythm of NAD+ synthesis. The one trial that tested timing directly found afternoon dosing better for lower-limb function and drowsiness.
Half-life and dosing frequency
Split above 500 mg/day
Metabolites peak near two hours and clear within about five, so once-daily dosing does not sustain elevation across 24 hours.
Time to effect
Blood NAD+
Days–2 weeks
Rises within days and plateaus by about two weeks; the only effect that replicates across essentially every trial.
Blood pressure
8–12 weeks
Trials that found blood-pressure changes measured them at 8 to 12 weeks; the effect is concentrated in adults aged 60 and over.
Sleep and walking
8–12 weeks
Sleep and walking changes were measured at 8 to 12 weeks, so a meaningful trial period is roughly three months.

Benefits

Contraindications
  • Pregnancy and lactation
  • Active malignancy, or within 5 years of a cancer diagnosis
  • Severe chronic kidney disease (eGFR below 30 mL/min/1.73 m²)
  • Child-Pugh Class B or C liver impairment
  • NAMPT-targeted oncology agents (daporinad, related NAMPT inhibitors)
    •
Key Interactions
  • Antihypertensive medications (amlodipine, lisinopril, losartan)
  • Over-the-counter niacin and niacinamide products
  • Other NAD+ precursors (nicotinamide riboside, NADH, nicotinamide, high-dose tryptophan)
  • Blood-pressure-lowering supplements (beetroot nitrate, magnesium, potassium, omega-3 fatty acids)
  • Methyl-donor supplements (betaine, methylfolate, methylcobalamin)
  • Intravenous NAD+ infusions
    •

Risk & Side Effects

  • High: Increased nicotinamide and methylated-metabolite load
    •
  • Medium: Mild gastrointestinal symptoms; reproductive-organ changes in rodent toxicology
  • Low: Potential acceleration of existing cancers; amplification of senescent-cell inflammatory signaling; unpredictable gut-microbiome effects; blunted mitochondrial adaptation to training
  • Speculative: Age-specific kidney inflammation; methyl-group diversion and rising homocysteine

Monitoring

Marker Target Why
Whole-blood NAD+ No established target; track change from the individual's own baseline Confirms the supplement is absorbed and active
Blood pressure (home average) 105–120 / 65–78 mmHg The endpoint with the most consistent trial evidence
Fasting insulin 2–6 µIU/mL Detects the insulin-resistance improvement seen in the clamp trial
HOMA-IR Below 1.5 Calculated index of insulin resistance, the target of the strongest positive trial
HbA1c 4.8–5.3% Three-month average blood sugar; meta-analyses found no NMN effect, so a rise signals something else
ALT 10–26 U/L (men), 8–22 U/L (women) Screens for the hepatic load implied by high nicotinamide clearance
eGFR Above 90 mL/min/1.73 m² Addresses the aging-specific kidney inflammation seen in rodent work
Homocysteine 5–7 µmol/L Tests the theoretical methyl-group drain from clearing nicotinamide
hs-CRP Below 0.8 mg/L Watches for the senescence-related inflammatory signal flagged in laboratory work

Cadence: Full panel at baseline, repeated at 12 weeks, then every 6–12 months; home blood pressure weekly for the first month.

Qualitative Assessment

  • Sleep quality and how rested mornings feel, ideally scored with a standard sleep questionnaire before starting and at 12 weeks
  • Daytime drowsiness, the specific endpoint that moved in the timing trial
  • Perceived exertion and recovery during regular endurance sessions
  • Ease of rising from a chair and habitual walking pace
  • Gastrointestinal comfort, the most common reason for discontinuation
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.